SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001785530-22-000021
Filing Date
2022-05-10
Accepted
2022-05-10 07:04:39
Documents
50
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q howl-20220331.htm   iXBRL 10-Q 1232761
2 EX-10.1 a03312022ex101.htm EX-10.1 587732
3 EX-31.1 a03312022ex311.htm EX-31.1 9636
4 EX-31.2 a03312022ex312.htm EX-31.2 9657
5 EX-32.1 a03312022ex321.htm EX-32.1 7169
  Complete submission text file 0001785530-22-000021.txt   4816474

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20220331.xsd EX-101.SCH 22700
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT howl-20220331_cal.xml EX-101.CAL 33773
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT howl-20220331_def.xml EX-101.DEF 147028
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20220331_lab.xml EX-101.LAB 355997
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20220331_pre.xml EX-101.PRE 234358
44 EXTRACTED XBRL INSTANCE DOCUMENT howl-20220331_htm.xml XML 447655
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40366 | Film No.: 22907305
SIC: 2834 Pharmaceutical Preparations